Blurbs

Analysts Conflicted on These Healthcare Names: Hookipa Pharma (HOOK), Olink Holding (OLK) and Pfizer (PFE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hookipa Pharma (HOOKResearch Report), Olink Holding (OLKResearch Report) and Pfizer (PFEResearch Report).

Hookipa Pharma (HOOK)

SVB Securities analyst Andrew Berens maintained a Buy rating on Hookipa Pharma yesterday. The company’s shares closed last Monday at $1.55, close to its 52-week low of $1.25.

According to TipRanks.com, Berens is a 3-star analyst with an average return of 1.2% and a 50.4% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hookipa Pharma with a $7.33 average price target, a 372.9% upside from current levels. In a report issued on August 11, RBC Capital also maintained a Buy rating on the stock with a $8.00 price target.

See today’s best-performing stocks on TipRanks >>

Olink Holding (OLK)

In a report issued on August 18, Puneet Souda from SVB Securities reiterated a Buy rating on Olink Holding, with a price target of $25.00. The company’s shares closed last Monday at $16.68.

According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.8% and a 38.9% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Olink Holding with a $19.00 average price target.

Pfizer (PFE)

In a report released yesterday, David Risinger from SVB Securities maintained a Hold rating on Pfizer, with a price target of $53.00. The company’s shares closed last Monday at $48.90.

According to TipRanks.com, Risinger is a 2-star analyst with an average return of -0.6% and a 35.7% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Prometheus Biosciences, and Theravance Biopharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $57.64 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HOOK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed